Key Takeaways
- A post-detox plan should be built on ASAM’s six-dimension assessment, with placement driven by scored results across withdrawal, biomedical, psychiatric, readiness, relapse potential, and recovery environment 5.
- For opioid use disorder, medication matters more than setting: MOUD was linked to roughly a 55% lower overdose risk, while residential care showed no overdose advantage over outpatient 2.
- Trauma work belongs alongside SUD treatment, not after it. Current VA/DoD guidance directs concurrent evidence-based care for co-occurring PTSD and SUD rather than sequenced abstinence gates 11.
- Insist on measurement-based review at 3, 6, and 12 months using scored instruments, and question retention design—about half of clients don’t complete even well-run programs 1.
The Post-Detox Inflection Point
You’ve made it through detox. That took real work, and the ground under you probably still feels unfamiliar. The next decision you make—what happens in the weeks after your body clears—will shape whether the gains you just fought for compound into something durable or quietly slip away.
This is the window where a substance abuse treatment plan stops being a form and starts being the clinical instrument that carries you forward. Post-detox is when the plan’s architecture matters most, because acute stabilization has ended and the underlying drivers of use—trauma, depression, anxiety, pain, environment—are back in the room without the buffer of active substances.
You already understand the fundamentals. You know detox isn’t treatment. You know relapse rates track more closely with what happens after discharge than with what happened during withdrawal. What you need now is a framework for evaluating what the next 30, 60, and 90 days should actually contain—and how that plan should adapt when your symptoms, biometrics, and life circumstances shift over the coming year.
A well-built plan is not a static document. It matches your level of care to a multidimensional assessment, integrates trauma-focused therapy alongside substance use work rather than deferring it, and includes explicit checkpoints where clinicians revise the plan based on what the data show at 3, 6, and 12 months 1. The rest of this article walks through what that architecture looks like, where the evidence is strong, and where honest trade-offs exist.
The Six-Dimension Assessment That Drives Placement
What ASAM’s Fourth Edition Actually Measures
Your plan’s placement decision doesn’t start with a bed or a schedule. It starts with an assessment across six dimensions that, together, describe where you actually are clinically—not where a program has capacity.
The ASAM Criteria 4th Edition organizes this around: (1) intoxication, withdrawal, and addiction medications; (2) biomedical conditions; (3) psychiatric and cognitive conditions; (4) substance use and change readiness; (5) continued use or continued problem potential; and (6) recovery environment and person-centered considerations 5. Each dimension is scored on its own, and no single dimension decides your level of care. A stable withdrawal picture can still be paired with an unstable psychiatric dimension or a recovery environment that puts you next door to your last dealer.
Those six dimensions map to a set of levels: Level 0.5 early intervention, Level 1 outpatient, Level 2 intensive or high-intensity outpatient (including PHP at the higher end of Level 2), Level 3 residential, and Level 4 medically managed inpatient 5. Post-detox, most of the meaningful decisions live between Level 2 and Level 3.
Ask to see your scores in each dimension, not just the recommended level. If your clinician can name why Dimension 3 or Dimension 6 pushed the recommendation up or down, the assessment was done as intended. If the answer is vague, the placement is likely being driven by something other than the criteria—capacity, insurance authorization, or habit—and your plan is starting on a weaker foundation than it should.
Matching Levels of Care to the Assessment
Once your dimensions are scored, the plan has to answer a harder question: what intensity actually fits the profile, and for how long?
A Dimension 3 score reflecting active PTSD symptoms, unmanaged depression, or suicidal ideation typically pulls placement toward Level 3 residential or the higher end of Level 2. A Dimension 6 score that includes housing instability, an active-use partner at home, or no daytime structure does similar work—even when withdrawal and biomedical dimensions look calm. The point of the criteria is that a person can be biologically stable and clinically unsafe at the same time 5.
Where the assessment shows a supportive environment, engaged social supports, and mental health symptoms that are moderate rather than acute, Level 2.1 IOP or Level 2.5 PHP often does the work residential would do, with less disruption to employment and family. The 4th Edition explicitly builds this flexibility in; it does not treat residential as the default upgrade whenever detox ends 5.
Two things your plan should specify at this stage. First, the criteria that would move you down a level—typically stable symptom scores over a defined window, medication adherence, and a viable living situation. Second, the criteria that would move you back up. A plan that only describes step-downs assumes recovery is linear. Yours won’t be, and the document should say so before you need it to. Placement is a decision the plan revisits, not a verdict it delivers.
Residential Isn’t Automatically Better: The Evidence on Setting
Post-detox, the pull toward residential care is understandable. You’ve earned some stability and you want a container that protects it. Just don’t let the container question overshadow the medication question—because for opioid use disorder specifically, the evidence points somewhere the marketing rarely does.
A 2022 cohort study compared residential and outpatient treatment for adults with opioid use disorder and found that residential care was not associated with reductions in opioid overdose or opioid-related ED and hospital encounters compared to outpatient treatment. Residential did show higher retention at six months (aOR 1.71), but that advantage faded by one year 2. The variable that actually moved the overdose needle was medication: patients receiving buprenorphine, methadone, or naltrexone had roughly a 55% lower overdose risk than those who didn’t, with an adjusted hazard ratio of 0.45 2.
Read that carefully. It doesn’t mean residential is wrong for you. It means setting is a weaker predictor of survival than what your plan actually prescribes inside the setting. A residential program without MOUD is a worse safety plan for OUD than an outpatient program with MOUD. The same study noted, somewhat counterintuitively, that residential patients on MOUD showed higher ED/hospitalization rates, likely reflecting closer monitoring and lower thresholds for medical escalation rather than worse outcomes 2.
Two questions your plan should answer explicitly before you commit to a level of care. First: what medications are indicated for your substance use profile, and is the setting you’re considering equipped to start, continue, and titrate them without interruption? Second: if the setting can’t offer MOUD—or expects you to taper off before admission—what is the clinical justification, and does it survive scrutiny against current evidence?
Residential still earns its place. If your Dimension 6 environment is actively dangerous, if you need a break from cues you can’t yet navigate, if your last three outpatient attempts collapsed within days, the structure buys you something outpatient can’t replicate. But choose it for what it does well—concentrated therapy hours, environmental control, staff continuity—not because you assume it lowers overdose risk more than the medication does. It doesn’t 2.
Concurrent Trauma Treatment, Not Sequential
Why ‘Stabilize First’ Is Outdated Guidance
For years, the field operated on a reasonable-sounding assumption: get the substance use under control first, then open the trauma work once the client is stable. It kept clinicians out of situations they felt unequipped for, and it kept clients from being asked to process their worst memories while their nervous system was still recalibrating. The logic was protective. The outcomes it produced were not.
Current guidance moves in the opposite direction. The VA/DoD position is direct: patients with co-occurring PTSD and SUD should be offered evidence-based treatment for both conditions, and having one diagnosis should not be a barrier to receiving treatment for the other. Individuals with PTSD and SUD can safely engage in and benefit from trauma-focused psychotherapies alongside their addiction care 11. This is not a soft preference. It is a shift away from the sequencing model that kept trauma work locked behind an abstinence gate many clients never reached.
The reason sequencing fails you is straightforward. The symptoms driving your use—intrusive memories, hyperarousal, avoidance, sleep collapse—do not politely wait for month three of sobriety. They intensify without the substances that were muting them. If your plan defers trauma work until you’ve earned it, the plan is asking you to hold the hardest ground with the fewest tools. That is not clinical caution. That is a design flaw the field has already named 8.
What Integrated Trauma Work Looks Like Inside the Plan
Integrated does not mean everything at once. It means both conditions have a named treatment track, a named clinician responsible for each, and coordination between them written into the plan rather than left to hallway conversations.
In practice, your plan should specify which trauma-focused modality is being offered—Prolonged Exposure, Cognitive Processing Therapy, EMDR, or an integrated CBT protocol—and the cadence at which it runs alongside your SUD sessions 11. It should also be honest about what integration does and doesn’t do. The ICBT randomized trial found that integrated cognitive behavioral therapy produced superior outcomes on drug use compared with individual addiction counseling and standard care, but did not show a clear advantage on PTSD symptom severity at six months 4. Read that as useful, not discouraging: integrating trauma-focused CBT into SUD treatment appears to help the substance use outcome specifically, while PTSD symptoms may need additional targeted work over a longer arc.
Three elements a working plan puts on paper. First, safety planning that names your specific triggers and the concrete responses—grounding techniques, contact points, medication protocols—you’ll use when they hit 3. Second, psychoeducation sessions early in the plan so you understand why your body reacts the way it does; this is not filler, it is the piece that keeps you engaged when exposure work gets hard 9. Third, explicit language about preventing retraumatization inside the treatment setting itself—how staff transitions, group composition, and physical spaces are handled so the environment doesn’t reproduce what you came in to heal from 3.
Dual Diagnosis Architecture When PTSD Is in the Room
If you’re reading this after detox, there’s roughly a coin-flip chance PTSD is sitting in the room with your substance use disorder. Comorbid PTSD and SUD show up in 43–50% of individuals seeking SUD treatment, and the combination produces worse outcomes than either diagnosis alone 6. Your plan has to be built for that reality, not adjusted for it later.
Dual diagnosis architecture means the plan treats PTSD and SUD as one clinical picture with two named tracks, coordinated by clinicians who share notes and revise together. Not two programs referring to each other. Not a primary diagnosis with the other listed as a footnote. The distinction matters because integrated trauma-informed substance use treatment is associated with improved retention in adults compared with standard care, and that retention gain is where most of the downstream mental health improvement lives 6.
Three structural elements your plan should name on paper. First, a validated PTSD assessment at intake and at each review point—not a checkbox but a scored instrument that can show movement or stagnation over time. Second, a specified trauma-focused modality with a start date, not a promise that trauma work will begin “when you’re ready.” Readiness is not a milestone the plan waits for; it’s a condition the plan actively builds through psychoeducation, safety planning, and stabilization work happening in parallel 9. Third, an explicit protocol for what happens when trauma work destabilizes substance use—because sometimes it will. Symptom flare during exposure work is not evidence the sequencing was wrong. It’s evidence the coordination needs to tighten.
One honest note. A systematic review of trauma-informed care across SUD settings found consistently positive results on substance use, mental health symptoms, and retention, but the underlying studies vary in quality 7. Treat that as a reason to insist your plan measures its own outcomes, not a reason to accept a less integrated design.
What a Working Plan Produces at 3, 6, and 12 Months
You should expect your plan to produce measurable change, and you should expect it on a timeline you can see. “Better” is not a clinical endpoint. Substance involvement scores, standardized depression and anxiety measures, PTSD symptom severity, and retention checkpoints are.
The most concrete picture of what a well-run trauma-informed plan produces comes from a 2025 residential cohort study. In that program, the trauma-informed care model was delivered as intended about 88% of the time. Substance involvement dropped meaningfully at the three-month mark, with an effect size of d=0.67—a large effect by clinical research standards, not a marginal one. Depression, anxiety, and PTSD symptoms also improved across the 3-, 6-, and 12-month follow-ups 1. Only 48% of clients completed the full six-week program 1. Hold those two facts next to each other. Among people who stayed, the trajectory was strong. Among the group as a whole, roughly half didn’t finish the intended dose.
What this means for your plan is specific. First, ask what standardized instruments will be used to track your substance involvement, mood, and trauma symptoms, and at what intervals. If your plan has no scored follow-up at 3, 6, and 12 months, it cannot tell you whether it’s working—it can only tell you whether you’re still in the room. Second, ask what the program’s own completion rate looks like and what they’ve built to move it. The 48% figure is not an indictment of trauma-informed residential care; it’s the field’s honest baseline, and it is the number your plan’s retention design has to beat 1.
An effect size of d=0.67 at three months is what a plan can produce when the model is delivered with fidelity and you stay engaged. Both conditions matter. The plan holds up its end when its structure and measurement are real. You hold up yours by staying long enough for the trajectory to compound. The next section takes the retention half of that equation seriously, because a plan that produces good outcomes only for the half that finishes is a plan with a design problem to solve.
Retention as a Design Problem the Plan Must Solve
Half the people who start a well-run trauma-informed residential program don’t finish it 1. That is not a fact to hide from you. It is the design problem your plan has to solve before it can produce the outcomes the same research shows are possible for the people who stay.
Retention is often framed as a patient variable—motivation, readiness, willingness to do the work. Treat that framing skeptically. When roughly half of clients drop out of programs delivered with 88% fidelity to the intended model 1, the more useful question is what the plan itself is doing to hold people through the weeks when the work gets hardest. The systematic review of trauma-informed care in SUD settings points in the same direction: programs that integrated trauma awareness into how services were delivered saw better retention and client satisfaction than standard care 7. The structural choices matter.
Ask your plan to name its retention design in specific terms. Not “we support engagement.” Concrete elements: how the first two weeks are structured differently from weeks three through six, when peer support enters, how missed sessions trigger outreach rather than discharge, what happens if you use again mid-treatment. A plan that treats a lapse as a signal to tighten coordination will hold you differently than one that treats it as a violation.
Trigger management belongs on this list. TIP 57 names identifying and managing trauma-related triggers as a core clinical objective, alongside psychoeducation and empowerment 3. When those objectives are built into your daily schedule—not saved for a single group per week—the week you most want to leave is the week the plan is best equipped to keep you.
Your job is to stay. The plan’s job is to make staying possible.
Measurement-Based Adjustment: How the Plan Actually Adapts
A plan that doesn’t change is a plan that isn’t listening. The clinical instrument you sign at week one should look different by week six, different again at three months, and meaningfully revised by the twelve-month mark. What drives those revisions is data—not clinician impression, not your self-report alone, but scored instruments applied at defined intervals so the plan can respond to what’s actually happening.
VA/DoD guidance on co-occurring PTSD and SUD names this explicitly: shared decision-making and measurement-based care are treatment standards, not optional add-ons 11. In practice, that means your plan carries a small set of validated instruments—something like the PHQ-9 for depression, GAD-7 for anxiety, PCL-5 for PTSD, and a substance involvement measure—readministered on a schedule you can see. Scores go into the record. Scores drive the next conversation.
Three adjustments the data should trigger. If your PTSD scores plateau while your substance use scores improve, the trauma-focused modality needs revision or intensification—the ICBT trial is a reminder that substance outcomes and trauma symptoms don’t always move together 4. If retention risk climbs (missed sessions, flattening engagement), the plan tightens frequency and adds outreach before discharge is on the table. If your recovery environment shifts—new job, housing change, family stressor—Dimension 6 gets rescored and the level of care is revisited, not assumed 5.
Ask, at intake, when your next formal plan review is scheduled and what would prompt an unscheduled one. That answer tells you whether the plan is a living instrument or a filed document.
Questions to Ask Before You Sign the Plan
You’ve read enough now to walk into the intake conversation as a peer, not a passenger. The document in front of you is negotiable. Bring these questions, and pay attention to which ones the clinician answers with specifics.
What did I score in each of the six ASAM dimensions, and which ones drove the level-of-care recommendation 5? What standardized instruments will track my substance involvement, depression, anxiety, and PTSD symptoms, and when are they readministered? What trauma-focused modality is being offered, when does it start, and how is it coordinated with my SUD work rather than deferred until later 11? If opioids are part of the picture, what medication is indicated and can this setting start and continue it without a taper requirement 2? What is your program’s completion rate, and what specific structural elements are designed to hold people through weeks three through six 1? When is my next formal plan review, and what circumstances trigger an unscheduled one?
If the answers are concrete, the plan is a clinical instrument. If they’re vague, keep asking. You’ve already done the hardest work by getting here. The plan you sign should be worthy of it.
Start building your personalized recovery plan today
Connect with a team ready to guide your next steps toward lasting recovery and support.
Frequently Asked Questions
How long should a substance abuse treatment plan last after detox?
There isn’t a universal length. Your plan’s duration should track your six-dimension assessment scores and how they move over time, not a fixed calendar 5. A common architecture runs 30–90 days of higher-intensity care (Level 2.5 or Level 3) followed by step-down outpatient and long-term recovery monitoring. Expect the plan to be revised at 3, 6, and 12 months based on scored outcomes 1.
Should I choose residential care or intensive outpatient after detox?
It depends on what your assessment shows, not on which setting feels safer. For opioid use disorder specifically, residential care was not associated with reductions in overdose compared with outpatient; medication (MOUD) was the variable that lowered overdose risk substantially 2. Choose residential when your recovery environment is unsafe or symptoms are acute. Choose outpatient when supports are stable and MOUD access is continuous.
Can I start trauma therapy before I have extended sobriety?
Yes, and current guidance says you should. The VA/DoD position is that patients with co-occurring PTSD and SUD should be offered evidence-based treatment for both, and having one diagnosis should not block treatment for the other 11. Trauma-focused therapies like PE, CPT, and EMDR can be delivered safely alongside SUD care. Ask your clinician which modality starts, when, and how it coordinates with your addiction work.
How often should my treatment plan be reviewed and updated?
Formal reviews should happen at defined intervals with scored instruments, not just when something breaks. VA/DoD guidance names measurement-based care as a standard, meaning tools like PHQ-9, GAD-7, and PCL-5 drive the next revision 11. Expect reviews at minimum every 30 days in higher-intensity care and at 3, 6, and 12 months long-term 1. Ask what circumstances would trigger an unscheduled review.
What role does medication play inside the treatment plan for opioid use disorder?
Medication is the single most consequential clinical decision inside an OUD plan. In a 2022 cohort study, MOUD use was associated with an adjusted hazard ratio of 0.45 for overdose—roughly a 55% risk reduction—regardless of whether care was residential or outpatient 2. If your plan defers, tapers, or excludes buprenorphine, methadone, or naltrexone without a clear clinical justification, that gap is worth challenging before you sign.
What should I do if I don’t complete the initial program length?
You’re not alone, and it isn’t a verdict. Roughly half of clients in a well-run trauma-informed residential program didn’t complete the full six weeks 1. Treat an early exit as a signal to tighten coordination, not to walk away from care. Re-engage at the next appropriate level—PHP, IOP, or a return to residential—and ask the receiving program to build retention structure into the first two weeks specifically.
References
- Feasibility and outcomes of a trauma-informed model of care in residential substance use services. https://pubmed.ncbi.nlm.nih.gov/39566845/
- Association between treatment setting and outcomes among opioid use disorder patients treated in a residential or outpatient setting. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389731/
- TIP 57: Trauma-Informed Care in Behavioral Health Services (Full PDF). https://library.samhsa.gov/sites/default/files/sma14-4816.pdf
- A randomized controlled trial of treatments for co-occurring substance use disorders and PTSD. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478141/
- ASAM Criteria Fourth Edition (Medicaid 1115 SUD Webinar Slides). https://www.medicaid.gov/medicaid/section-1115-demonstrations/downloads/1115-sud-asam-webinar-slides.pdf
- Study protocol: implementing and evaluating a trauma-informed substance use treatment program in outpatient substance use disorder treatment settings. https://pmc.ncbi.nlm.nih.gov/articles/PMC10572352/
- A Systematic Review of Trauma-Informed Care in Substance Use Treatment Settings. https://pubmed.ncbi.nlm.nih.gov/39641885/
- The Necessity of a Trauma-Informed Paradigm in Substance Use Treatment. https://pubmed.ncbi.nlm.nih.gov/34334012/
- Trauma-Informed Care in Behavioral Health Services (TIP Series 57 – Full PDF). https://library.samhsa.gov/sites/default/files/sma15-4420.pdf
- Trauma-Informed Care in Behavioral Health Services (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK207201/
- Treatment of Co-Occurring PTSD and Substance Use Disorders in VA. https://www.ptsd.va.gov/professional/treat/cooccurring/tx_sud_va.asp
- Association between treatment setting and outcomes among opioid use disorder patients treated in a residential or outpatient setting. https://pmc.ncbi.nlm.nih.gov/articles/PMC9389731/